RaySearch Laboratories AB (publ) (0GRZ.L)
- Previous Close
67.70 - Open
69.00 - Bid --
- Ask --
- Day's Range
69.00 - 69.00 - 52 Week Range
45.12 - 87.00 - Volume
86 - Avg. Volume
5,417 - Market Cap (intraday)
-- - Beta (5Y Monthly) 1.23
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment in the Asia-Pacific, the Middle East, the Americas, Europe, and Africa. It develops and markets RayStation, a treatment planning system; RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy; and RayCare, an oncology information. In addition, it offers µ-RayStation, a software platform for planning and evaluation in small animal irradiation research; RayCommand, a treatment control system that serves as link between the treatment machine and the treatment planning and oncology information systems; and RayIntelligence, a cloud-based oncology analytics system that turns patient data into insights. Further, the company provides training courses related to its products. RaySearch Laboratories AB (publ) is headquartered in Stockholm, Sweden.
www.raysearchlabs.com388
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: 0GRZ.L
Performance Overview: 0GRZ.L
Trailing total returns as of 4/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0GRZ.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0GRZ.L
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
7.98%
Return on Assets (ttm)
3.75%
Return on Equity (ttm)
11.72%
Revenue (ttm)
1.02B
Net Income Avi to Common (ttm)
81.57M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
343.68M
Total Debt/Equity (mrq)
72.12%
Levered Free Cash Flow (ttm)
154.5M
Company Insights: 0GRZ.L
0GRZ.L does not have Company Insights